Acalisib

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAcalisib
Drug Alias Nameacalisibum阿卡利司阿卡利塞GS-9820CAL-120
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsLymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A